Belfast Telegraph

UK Website Of The Year

Drugmaker Pfizer signs £1.2bn deal

By Kalyeena Makortoff

Published 25/08/2016

AstraZeneca has signed a $1.6bn (£1.2bn) deal to sell part of its antibiotics business to fellow pharmaceuticals giant Pfizer
AstraZeneca has signed a $1.6bn (£1.2bn) deal to sell part of its antibiotics business to fellow pharmaceuticals giant Pfizer

AstraZeneca has signed a $1.6bn (£1.2bn) deal to sell part of its antibiotics business to fellow pharmaceuticals giant Pfizer.

The Viagra-maker is set to pay $550m (£379m) to AstraZeneca up-front and another $175m (£130m) in January 2019.

The remaining amount will be paid out as manufacturing and sales develop.

The deal includes the commercial and development rights to AstraZeneca's late-stage small molecule antibiotics business and "recurring, double-digit royalties" on the sale of select drugs including antibiotic Zavicefta.

The rights will be valid across most global markets outside the US, AstraZeneca said.

The deal is expected to be finalised during the fourth quarter of 2016, but AstraZeneca said it will not impact the company's full-year outlook. Pfizer is also to acquire drug company Medivation for around £14bn (£10.6bn).

Belfast Telegraph

Your Comments

COMMENT RULES: Comments that are judged to be defamatory, abusive or in bad taste are not acceptable and contributors who consistently fall below certain criteria will be permanently blacklisted. The moderator will not enter into debate with individual contributors and the moderator’s decision is final. It is Belfast Telegraph policy to close comments on court cases, tribunals and active legal investigations. We may also close comments on articles which are being targeted for abuse. Problems with commenting? customercare@belfasttelegraph.co.uk

Read More

From Belfast Telegraph